ARC nuclease

Gene-editing upstart lays out a $100M IPO with a plan to quickly leapfrog the leaders in their field
Endpoints
Mon, 03/4/19 - 09:57 am
gene editing
IPOs
ARC nuclease
ARCUS
Precision Biosciences